Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847626 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,711
- Enrollment target
NCT00847626 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,711 participants.
The verdict
NCT00847626, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,711 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.
Interventions
- DRUG Azilsartan medoxomil and chlorthalidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,711 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00847626
The ClinicalTrials.gov registry entry for NCT00847626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,711 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azilsartan medoxomil and chlorthalidone is the first listed.
NCT00847626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00847626 about?
NCT00847626 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension". The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.
What is the current status of trial NCT00847626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,711 participants. The study started on 2009-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00847626?
The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG).
Who is sponsoring clinical trial NCT00847626?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.